Pharmaceutical middlemen saw gross profits increase by 12% from 2017 to 2019, according to a report by the PBM Accountability Project . The report said the source of profits varied substantially and included common tactics such as spread pricing and retroactive claw back fees. “PBMs have been remarkably adept at creating clever ways to divert prescription drug savings away from health plan sponsors and patients and into their own growing profit,” Mark Blum, executive director of America’s Agenda, a founding...